Web Results

Effect of Cognitive Therapy With Antidepressant Medications vs - NCBI

www.ncbi.nlm.nih.gov/pmc/articles/PMC4315327/

Combined treatment enhanced the rate of recovery vs treatment with ADM alone ..... Julie Jacobs, PhD, Cory P. Newman, PhD, and Rita Ryan, PhD (University of ... reports being a consultant to Bristol-Myers Squibb, Cerecor, Inc, Cyberonics, .... Hollon SD, DeRubeis RJ, Shelton RC, et al. ... Beck AT, Freeman A, Davis DD.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non ...

www.nejm.org/doi/full/10.1056/NEJMoa1507643?af=R&rss=currentIssue

Sep 27, 2015 ... (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.) Full Text of Discussion... Read the Full Article.

112 F.3d - Volume 112 of the Federal Reporter, 3rd Series :: U.S. ...

law.justia.com/cases/federal/appellate-courts/F3/112/

Bristol-myers Squibb Caribbean, et al., Defendants, Appellees ... Carlyle Bernard and John Simino, Plaintiffs-appellants, v. .... Barry Davis, A/k/a "mark Johnson", Appellant ...... Midgley; Earl Cox; Fredhollis; Randy Spackman; Diversified Real Estate Ltd.;julie Tolleson, Defendants-appellees.dan C. Fore, Plaintiff-appellant,...

Notice of Hearing Session

www.uniset.ca/lloydata/LL_multidistrict.pdf

Apr 14, 2004 ... Motion of plaintiffs Madhavi Parvathaneni, et al., for centralization of the following actions in the ..... Elizabeth Davis, et al. v. Life Insurance ... Bristol-Myers Squibb Co., et al., C.A. No. 3:03-1668 ..... Julie K. Pullin v. Wyeth, et al.

Fusing Data Mining, Machine Learning and Traditional Statistics to ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0148195

Feb 5, 2016 ... Contributed equally to this work with: Julie A. Pasco, Michael Berk, Lana J. .... Citation: Dipnall JF, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, et al. ... Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, ...... Davis J, Maes M, Andreazza A, McGrath J, Tye S, Berk M. Towards a ...

Gene-Wide Analysis Detects Two New Susceptibility Genes for ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0094661

Jun 12, 2014 ... Affiliation: University of Bristol Institute of Clinical Neurosciences, ..... Citation: Escott-Price V, Bellenguez C, Wang L-S, Choi S-H, Harold D, Jones L, et al. .... University of Arizona, R01 AG031581; University of California, Davis, P30 ... AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai ...

Articles - American Bar Association

www.americanbar.org/content/dam/aba/publications/antitrust_law/at301000_articles.pdf

C. Davis L. Rev. ... methods with anticompetitive effects such as in McDonald v. ..... Bristol-Myers Squibb Co., Bristol-Myers to Pay $670 Million to Settle ..... Ralph S. Tyler et al., The First Amendment and “Off-Label” Promotion, Drug and Medical .... Julie Brill, Competition and Consumer Protection: Strange Bedfellows or Best  ...

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non ...

jco.ascopubs.org/content/early/2015/09/17/JCO.2015.61.8918.full

Aug 31, 2015 ... ... MD, University of California, Davis, Comprehensive Cancer Center, 4501 X St, ... DFS favored erlotinib (median, 46.4 v 28.5 months; hazard ratio, 0.61; 95% CI, ..... Boehringer Ingelheim, Merck, Merck Serono, Bristol-Myers Squibb, ... Julie D. Horan ... Strauss GM,; Herndon JE 2nd,; Maddaus MA,; et al.

Identification of Cancer Care and Protocol Characteristics ...

jco.ascopubs.org/content/26/27/4458.full

Sep 20, 2008 ... Lastly, Mills et al conducted a systematic review to assess barriers at the patient level. ..... Consultant or Advisory Role: Julie Lemieux, Abraxis (C), Bristol-Myers Squibb (C), ... Gross CP, Murthy V, Li Y, et al: Cancer trial enrollment after ... Davis SW, Nealon EO, Stone JC: Evaluation of the national cancer ...

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 ...

www.nature.com/ng/journal/v43/n5/abs/ng.801.html

Carrasquillo, M.M. et al. ..... Department of Neurology, University of Alabama at Birmingham, Birmingham, ... Jeffrey L Cummings,; John M Ringman &; Harry V Vinters ... Laboratory Medicine, University of California Davis, Sacramento, California, .... Inc. M.R.F. receives research funding from Bristol-Myers Squibb Company, ...

More Info

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of ...

www.ncbi.nlm.nih.gov

Julie A. Lemm, <sup>corresponding author</sup> ... BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus .... were synthesized by Bristol-Myers Squibb, as were HCV reference inhibitors HCV-796, a palm site 2 ..... was seen by Pelosi et al. in GT 1a replicons under selection with BMS-791325 either alone  ...

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated ...

www.nejm.org

May 31, 2015 ... (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.) Full Text of Discussion... Read the Full Article.

JAMA Network | JAMA | Three- vs Four-Drug Antiretroviral Regimens ...

jama.jamanetwork.com

Aug 16, 2006 ... ObjectiveTo compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. ... patients could substitute stavudine (Zerit, Bristol- Myers Squibb) for zidovudine, .... *Details reported in Gulick et al. ...... Jr, MD ( University of Minnesota); Paula Potter, RN, BSN, Julie Hoffman, RN, ...